The Cangrelor segmentation by application distinguishes four primary clinical uses that collectively shape the market’s revenue profile. Percutaneous Coronary Intervention (PCI) accounts for the largest share, driven by the drug’s rapid onset and reversible platelet inhibition, which are critical during high‑risk coronary stenting procedures. This segment contributes roughly 55 % of total sales, reflecting the high procedural volume and reimbursement favorability in interventional cardiology. Acute Coronary Syndrome (ACS) represents the second‑largest application, encompassing patients presenting with unstable angina or myocardial infarction where immediate antiplatelet activity is required; it generates about 30 % of market value. Cardiovascular surgery, including coronary artery bypass grafting, utilizes Cangrelor for intra‑operative platelet control, contributing an estimated 10 % of revenue due to lower procedure frequency but higher per‑case drug utilization. The residual Other category (approximately 5 %) captures off‑label or emerging indications such as peripheral artery disease interventions, where niche adoption adds modest incremental volume. Together, these application sub‑segments define the overall market size and growth dynamics.
